Heron Therapeutics reports Q3 2025 net revenue of $38.2 million

Reuters

Nov 04, 2025

Heron <a href="https://laohu8.com/S/LENZ">Therapeutics</a> reports Q3 2025 net revenue of $38.2 million

Heron Therapeutics reported net revenue of $38.2 million for the third quarter of 2025, bringing year-to-date net revenue to $114.3 million, a 10.4% increase compared to the prior year period. The company reaffirmed its 2025 full-year net revenue guidance of $153 million to $163 million and adjusted EBITDA guidance of $9.0 million to $13.0 million. ZYNRELEF net revenue grew 49% in the third quarter of 2025 compared to the same period in 2024, supported by the launch of the Vial Access Needle and an enhanced distributor incentive program. APONVIE net revenue increased 173% year-over-year for the quarter, driven by expanded adoption and a newly launched dedicated sales team. The Acute Care franchise achieved 67.2% revenue growth year-over-year in the third quarter and 69.2% growth for the first nine months of 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Heron Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9568238-en) on November 04, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2580317177"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2580317177\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2580317177?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-04 21:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2580317177","market":"fut","top_or_hot":-1,"title":"Heron Therapeutics reports Q3 2025 net revenue of $38.2 million","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Heron <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> reports Q3 2025 net revenue of $38.2 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Heron Therapeutics reported net revenue of $38.2 million for the third quarter of 2025, bringing year-to-date net revenue to $114.3 million, a 10.4% increase compared to the prior year period. The company reaffirmed its 2025 full-year net revenue guidance of $153 million to $163 million and adjusted EBITDA guidance of $9.0 million to $13.0 million. ZYNRELEF net revenue grew 49% in the third quarter of 2025 compared to the same period in 2024, supported by the launch of the Vial Access Needle and an enhanced distributor incentive program. APONVIE net revenue increased 173% year-over-year for the quarter, driven by expanded adoption and a newly launched dedicated sales team. The Acute Care franchise achieved 67.2% revenue growth year-over-year in the third quarter and 69.2% growth for the first nine months of 2025.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/HRTX\">Heron Therapeutics Inc.</a> published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9568238-en) on November 04, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Heron Therapeutics reports Q3 2025 net revenue of $38.2 million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHeron Therapeutics reports Q3 2025 net revenue of $38.2 million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-04 21:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Heron <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> reports Q3 2025 net revenue of $38.2 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Heron Therapeutics reported net revenue of $38.2 million for the third quarter of 2025, bringing year-to-date net revenue to $114.3 million, a 10.4% increase compared to the prior year period. The company reaffirmed its 2025 full-year net revenue guidance of $153 million to $163 million and adjusted EBITDA guidance of $9.0 million to $13.0 million. ZYNRELEF net revenue grew 49% in the third quarter of 2025 compared to the same period in 2024, supported by the launch of the Vial Access Needle and an enhanced distributor incentive program. APONVIE net revenue increased 173% year-over-year for the quarter, driven by expanded adoption and a newly launched dedicated sales team. The Acute Care franchise achieved 67.2% revenue growth year-over-year in the third quarter and 69.2% growth for the first nine months of 2025.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/HRTX\">Heron Therapeutics Inc.</a> published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9568238-en) on November 04, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00BGHQF748.EUR","symbol_name":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251104:nNDL7HRQ4c:1","article_id":"2580317177","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2580317177","pubTimestamp":1762261244,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Heron Therapeutics reported net revenue of $38.2 million for the third quarter of 2025, bringing year-to-date net revenue to $114.3 million, a 10.4% increase compared to the prior year period. The company reaffirmed its 2025 full-year net revenue guidance of $153 million to $163 million and adjusted EBITDA guidance of $9.0 million to $13.0 million. ZYNRELEF net revenue grew 49% in the third quarter of 2025 compared to the same period in 2024, supported by the launch of the Vial Access Needle and an enhanced distributor incentive program. APONVIE net revenue increased 173% year-over-year for the quarter, driven by expanded adoption and a newly launched dedicated sales team. The Acute Care franchise achieved 67.2% revenue growth year-over-year in the third quarter and 69.2% growth for the first nine months of 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","NDAQ":"纳斯达克OMX交易所","BK4588":"碎股","HRTX":"Heron Therapeutics Inc.","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","BK4112":"金融交易所和数据","BK4585":"ETF&股票定投概念","BK4139":"生物科技","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD"},"translate_title":"Heron Therapeutics报告2025年第三季度净收入为3820万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":0.9,"HRTX":0.9},"content_text":"Heron Therapeutics reports Q3 2025 net revenue of $38.2 million\n    \n\n        Heron Therapeutics reported net revenue of $38.2 million for the third quarter of 2025, bringing year-to-date net revenue to $114.3 million, a 10.4% increase compared to the prior year period. The company reaffirmed its 2025 full-year net revenue guidance of $153 million to $163 million and adjusted EBITDA guidance of $9.0 million to $13.0 million. ZYNRELEF net revenue grew 49% in the third quarter of 2025 compared to the same period in 2024, supported by the launch of the Vial Access Needle and an enhanced distributor incentive program. APONVIE net revenue increased 173% year-over-year for the quarter, driven by expanded adoption and a newly launched dedicated sales team. The Acute Care franchise achieved 67.2% revenue growth year-over-year in the third quarter and 69.2% growth for the first nine months of 2025.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Heron Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9568238-en) on November 04, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}